-
Treatment Options for Alopecia Areata in Children and Adolescents Pediatric Drugs (IF 3.7) Pub Date : 2024-03-11
Abstract Alopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following
-
Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA) Pediatric Drugs (IF 3.7) Pub Date : 2024-02-20
Abstract Systemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs
-
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs Pediatric Drugs (IF 3.7) Pub Date : 2024-02-04 Sarrah Lokhandwala, Jaiden Townsend, Coziana Ciurtin
-
Improving Methylphenidate Titration in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Controlled Trial Using Placebo-Controlled Titration Implemented in Clinical Practice Pediatric Drugs (IF 3.7) Pub Date : 2024-01-27 Karen Vertessen, Marjolein Luman, Pierre Bet, Catharina E. Bergwerff, Marco Bottelier, Reino Stoffelsen, James M. Swanson, Annemiek Wisse, Jos Twisk, Jaap Oosterlaan
-
Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations Pediatric Drugs (IF 3.7) Pub Date : 2024-01-27 Jaemaela del Rosario, Gerhard Fusch, Ali McBryde, Katelyn Sushko, John van den Anker, Samira Samiee-Zafarghandy
-
Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations Pediatric Drugs (IF 3.7) Pub Date : 2024-01-27
Abstract Objectives The management of vascular malformations is complex and challenging. This study aimed to explore efficacy, plasma trough concentrations of sirolimus, post-withdrawal conditions, and adverse reactions of sirolimus in treating complex vascular malformations. Methods In our center, we analyzed vascular malformations treated with sirolimus (and corticosteroid) from August 2017 to June
-
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis Pediatric Drugs (IF 3.7) Pub Date : 2024-01-24 Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Peter D. Arkwright, Lawrence F. Eichenfield, Michele Ramien, Faisal A. Khokhar, Zhen Chen, Annie Zhang, Sonya L. Cyr
-
Use of Computerized Physician Order Entry with Clinical Decision Support to Prevent Dose Errors in Pediatric Medication Orders: A Systematic Review Pediatric Drugs (IF 3.7) Pub Date : 2024-01-19
Abstract Background Prescribing is a high-risk task within the pediatric medication-use process and requires defenses to prevent errors. Such system-centric defenses include electronic health record systems with computerized physician order entry (CPOE) and clinical decision support (CDS) tools that assist safe prescribing. The objective of this study was to examine the effects of CPOE systems with
-
Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study Pediatric Drugs (IF 3.7) Pub Date : 2024-01-16 Khalid W. Taher, Razan Almofada, Sufyan Alomair, Ahmed A. Albassam, Abdullah Alsultan
Background and Objective Voriconazole pharmacokinetics are highly variable in pediatric patients, and the optimal dosage has yet to be determined. The purpose of this study was to describe voriconazole pharmacokinetic and pharmacodynamic targets achieved and evaluate the efficacy and safety of voriconazole for critically ill pediatrics. Methods This is a single-center retrospective study conducted
-
Safety and Effectiveness of Prucalopride in Children with Functional Constipation with and without Upper Symptoms Pediatric Drugs (IF 3.7) Pub Date : 2024-01-04 Alejandro Velez, Ajay Kaul, Khalil I. El-Chammas, Lesley Knowlton, Erick Madis, Rashmi Sahay, Lin Fei, Sarah Stiehl, Neha R. Santucci
-
Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System Pediatric Drugs (IF 3.7) Pub Date : 2023-12-28 Guangfei Wang, Jinglin Wang, Ruxiang Du, Yi Wang, Zhiping Li
-
Managing Lupus Nephritis in Children and Adolescents Pediatric Drugs (IF 3.7) Pub Date : 2023-12-20 Eugene Yu-hin Chan, Fiona Fung-yee Lai, Alison Lap-tak Ma, Tak Mao Chan
-
Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review Pediatric Drugs (IF 3.7) Pub Date : 2023-12-13 Torsten Joerger, Molly Hayes, Connor Stinson, Ibram Mikhail, Kevin J. Downes
-
Bosutinib: Pediatric First Approval Pediatric Drugs (IF 3.7) Pub Date : 2023-12-07 Sheridan M. Hoy
Bosutinib (BOSULIF®), an orally administered BCR–ABL tyrosine kinase inhibitor (TKI) developed by Pfizer Inc., is well established in the EU and the USA as a treatment for adults with newly diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), and for CP, accelerated phase and blast phase Ph+ CML that is resistant or intolerant (R/I) to prior therapy
-
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date Pediatric Drugs (IF 3.7) Pub Date : 2023-11-30 Charl Verwey, Ziyaad Dangor, Shabir A. Madhi
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™–AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for
-
Cantharidin Topical Solution 0.7%: First Approval Pediatric Drugs (IF 3.7) Pub Date : 2023-11-25 Susan J. Keam
Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant naturally derived from blister beetles) delivered via a single-use applicator that has been developed by Verrica Pharmaceuticals Inc. for the treatment of molluscum contagiosum and is also being developed for the treatment of warts. In July 2023, YCANTH™ (cantharidin
-
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach Pediatric Drugs (IF 3.7) Pub Date : 2023-11-17 Naïm Bouazza, Gilles Cambonie, Cyril Flamant, Aline Rideau, Manon Tauzin, Juliana Patkai, Géraldine Gascoin, Mirka Lumia, Outi Aikio, Gabrielle Lui, Léo Froelicher Bournaud, Aisling Walsh-Papageorgiou, Marine Tortigue, Alban-Elouen Baruteau, Jaana Kallio, Mikko Hallman, Alpha Diallo, Léa Levoyer, Jean-Marc Treluyer, Jean-Christophe Roze
-
Emerging Treatments for Childhood Interstitial Lung Disease Pediatric Drugs (IF 3.7) Pub Date : 2023-11-10 Nicol Bernardinello, Matthias Griese, Raphaël Borie, Paolo Spagnolo
-
Correction to: Viloxazine: Pediatric First Approval. Pediatric Drugs (IF 3.7) Pub Date : 2023-11-01 Yvette N Lamb
-
Practical Questions About Rescue Medications for Acute Treatment of Seizure Clusters in Children and Adolescents with Epilepsy in the USA: Expanding Treatment Options to Address Unmet Needs Pediatric Drugs (IF 3.7) Pub Date : 2023-10-30 James W. Wheless, Barry Gidal, Adrian L. Rabinowicz, Enrique Carrazana
-
Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies Pediatric Drugs (IF 3.7) Pub Date : 2023-10-17 Erina Lie, Mira Choi, Sheng-Pei Wang, Lawrence F. Eichenfield
Psoriasis is a chronic immune-mediated disorder that commonly affects adults and children. In recent years, pediatric psoriasis has increased in prevalence and the disease is often associated with various comorbidities and psychological distress. The conventional topical treatments for psoriasis, such as corticosteroids, calcineurin inhibitors, vitamin D analogs, anthralin, and coal tar, are often
-
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants Pediatric Drugs (IF 3.7) Pub Date : 2023-10-13 Yahiya Y. Syed
Pfizer is developing a bivalent respiratory syncytial virus (RSV) prefusion F subunit vaccine (RSVpreF; ABRYSVO™) for preventing RSV illness in infants and individuals aged ≥ 60 years. RSVpreF received approval for vaccination of pregnant individuals to help protect infants against RSV illness on 21 August 2023 in the USA. RSVpreF is also approved in the USA (31 May 2023) for active immunization of
-
Pediatric Drugs, Accelerated Approval, and Prospects for Reform. Pediatric Drugs (IF 3.7) Pub Date : 2023-10-14 Jeromie Ballreich,Hyung-Seok Kim,Mariana Socal
-
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients Pediatric Drugs (IF 3.7) Pub Date : 2023-10-04 Ai Tien Nguyen, Isabelle Koné-Paut, Perrine Dusser
-
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease Pediatric Drugs (IF 3.7) Pub Date : 2023-10-03 Christopher Towe, Alexei A. Grom, Grant S. Schulert
-
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options Pediatric Drugs (IF 3.7) Pub Date : 2023-10-02 Nicholas Chiang, Cathryn Sibbald, Rebecca Levy, Irene Lara-Corrales
-
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward Pediatric Drugs (IF 3.7) Pub Date : 2023-09-29 Narendra Kumar Bagri, Christine Chew, A. V. Ramanan
-
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial Pediatric Drugs (IF 3.7) Pub Date : 2023-09-15 Clément Chollat, Fabien Tourrel, Estelle Houivet, Romain Gillet, Eric Verspyck, Maryline Lecointre, Stéphane Marret, Vincent Compère
-
Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015) Pediatric Drugs (IF 3.7) Pub Date : 2023-09-11 Alba Rubio-San-Simón, Natasha K. A. van Eijkelenburg, Raoull Hoogendijk, Henrik Hasle, Charlotte M. Niemeyer, Michael N. Dworzak, Marco Zecca, Marta Lopez-Yurda, Julie M. Janssen, Alwin D. R. Huitema, Marry M. van den Heuvel-Eibrink, Eric J. Laille, Harm van Tinteren, Christian M. Zwaan
-
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab Pediatric Drugs (IF 3.7) Pub Date : 2023-09-02 Yoni E. van Dijk, Niels W. Rutjes, Korneliusz Golebski, Havva Şahin, Simone Hashimoto, Anke-Hilse Maitland-van der Zee, Susanne J. H. Vijverberg
-
Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors Pediatric Drugs (IF 3.7) Pub Date : 2023-08-28 Bibhuti Das
-
The Future of Advanced Therapies for Pediatric Crohn’s Disease Pediatric Drugs (IF 3.7) Pub Date : 2023-08-23 Julie Gallagher, Joel R. Rosh, Benjamin Sahn
Pediatric Crohn’s disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to
-
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit Pediatric Drugs (IF 3.7) Pub Date : 2023-08-07 Reuth Nir, Francesca Sperotto, Manasee Godsay, Minmin Lu, John N. Kheir
-
Fetal, Preterm, and Term Neonate Exposure to Remifentanil: A Systematic Review of Efficacy and Safety Pediatric Drugs (IF 3.7) Pub Date : 2023-08-04 Arielle Maroni, Marie-Stéphanie Aubelle, Clément Chollat
-
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review Pediatric Drugs (IF 3.7) Pub Date : 2023-08-01 Shengbo Fang, Sixi Zhang, Chunyan Zhang, Libo Wang
-
Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature Pediatric Drugs (IF 3.7) Pub Date : 2023-07-21 Claire Yang, Natalie Rosenwasser, Xing Wang, Zheng Xu, Joshua Scheck, Markus D. Boos, Deepti Gupta, Heather A. Brandling-Bennet, Robert Sidbury, Ramesh S. Iyer, Yongdong Zhao
-
A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants Pediatric Drugs (IF 3.7) Pub Date : 2023-07-17 Jason Tan, Sonia Jeffries, Roxane Carr
Proton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are commonly used medications in neonates and infants for the treatment of gastroesophageal reflux disease (GERD), especially in neonatal intensive care units (NICUs). A literature review was conducted to evaluate the efficacy and safety of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) in preterm neonates
-
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Pediatric Patients During Extracorporeal Membrane Oxygenation: A Systematic Review Pediatric Drugs (IF 3.7) Pub Date : 2023-07-14 Marc-Alexandre Duceppe, Salmaan Kanji, Anh Thu Do, Ni Ruo, Yiorgos Alexandros Cavayas, Martin Albert, Maxime Robert-Halabi, Samara Zavalkoff, Laura Benichou, Gordan Samoukovic, David R. Williamson
-
20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval Pediatric Drugs (IF 3.7) Pub Date : 2023-07-13 Matt Shirley
20‑valent pneumococcal conjugate vaccine (PCV20; Prevnar 20®; Apexxnar®) is a pneumococcal conjugate vaccine (PCV) developed by Pfizer for active immunization for the prevention of pneumococcal infections. PCV20 has a similar structure and formulation to Pfizer’s 13-valent PCV (PCV13; Prevnar 13®; Prevenar 13®), with the addition of polysaccharides to target seven further Streptococcus pneumoniae serotypes
-
Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review Pediatric Drugs (IF 3.7) Pub Date : 2023-06-15 Anat Yerushalmy-Feler, Caroline Brauner, Shlomi Cohen
Inflammatory bowel disease (IBD) is a chronic systemic immune-mediated disorder. The disease is triggered and perpetuated by a complex interplay between genetic predisposition, dysregulated immune responses, and environmental factors. Pediatric IBD is considered to be more aggressive compared with adult-onset IBD, and commonly requires more intensive pharmacological and surgical treatments. Although
-
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series Pediatric Drugs (IF 3.7) Pub Date : 2023-06-16 Hüseyin Anıl Korkmaz, Ved Bhushan Arya, Ahmet Gönüllü, Fulya Coşkunol, Behzat Ozkan
-
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1–6 Months of Age Pediatric Drugs (IF 3.7) Pub Date : 2023-06-09 Chris D. Glover, John W. Berkenbosch, Mary B. Taylor, Nihar V. Patel, Byron Kaelin, Breanne H. Y. Gibson, John Zhong
-
Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature Pediatric Drugs (IF 3.7) Pub Date : 2023-06-07 Wei-Ling Yan, Fen-Ying Zhao, Min-Er Gu, Nan Liu, Xiao-Ping Guo, Xiao-Jun Xu
Background Ruxolitinib has been increasingly used in the treatment of steroid-refractory graft-versus-host disease (SR-GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients. However, there are limited data on the use of ruxolitinib in children. Objective This study aimed to assess the efficacy and toxicity of ruxolitinib in the treatment of SR-GVHD in children. Patients and
-
Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center Pediatric Drugs (IF 3.7) Pub Date : 2023-06-03 Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, Ina Michel-Behnke
-
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury Pediatric Drugs (IF 3.7) Pub Date : 2023-06-02 Manan Raina, Amani Ashraf, Anvitha Soundararajan, Anusree Krishna Mandal, Sidharth Kumar Sethi
-
Pitolisant: Pediatric First Approval Pediatric Drugs (IF 3.7) Pub Date : 2023-05-26 Susan J. Keam
Pitolisant (WAKIX®), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and children from the age of 6 years for the treatment
-
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey Pediatric Drugs (IF 3.7) Pub Date : 2023-05-24 Michael A. Haft, Helen H. Park, Stephanie S. Lee, Jessica M. Sprague, Amy S. Paller, Colleen H. Cotton, Jacob P. Thyssen, Lawrence F. Eichenfield
-
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors Pediatric Drugs (IF 3.7) Pub Date : 2023-05-19 Ashley V. Geerlinks, Oussama Abla
-
Cardiac Hypertrophy Associated with Insulin Therapy in Extremely Preterm Infants Pediatric Drugs (IF 3.7) Pub Date : 2023-05-19 Carlo Dani, Michele Luzzati, Iuri Corsini, Chiara Poggi, Venturella Vangi, Caterina Coviello, Simone Pratesi
Background In the neonatal period, cardiac hypertrophy (CH) has been commonly associated with hyperinsulinemic pathologies, and the first case of CH in an extremely preterm infant treated with insulin infusion has recently been reported. To confirm this association, we report a case series of patients who developed CH after insulin therapy. Methods Infants with gestational age < 30 weeks and birth
-
Pediatric Status Epilepticus: Treat Early and Avoid Delays Pediatric Drugs (IF 3.7) Pub Date : 2023-05-13 Lindsey A. Morgan, Jennifer B. Hrachovec, Howard P. Goodkin
-
Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review Pediatric Drugs (IF 3.7) Pub Date : 2023-05-04 Hadi Sahrai, Mahdi Hemmati-Ghavshough, Marzieh Shahrabi, Amir Hossein Jafari-Rouhi, Mohammad Solduzian
-
Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents Pediatric Drugs (IF 3.7) Pub Date : 2023-04-04 Bhuvana A. Setty, Ajami Gikandi, Steven G. DuBois
-
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Pediatric Drugs (IF 3.7) Pub Date : 2023-03-27 Risa Nasu, Douglas E. James, Emmanuel Chigutsa, Parag Garhyan, Yukiko Nagai
-
Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates Pediatric Drugs (IF 3.7) Pub Date : 2023-03-21 Saikumar Matcha, Jayashree Dillibatcha, Arun Prasath Raju, Bhim Bahadur Chaudhari, Sudheer Moorkoth, Leslie E. Lewis, Surulivelrajan Mallayasamy
-
An Update of Pharmacological Management in Children with Functional Constipation Pediatric Drugs (IF 3.7) Pub Date : 2023-03-20 Anna de Geus, Ilan J. N. Koppen, Robert B. Flint, Marc A. Benninga, Merit M. Tabbers
Functional constipation is a common problem in childhood worldwide and has a great impact on social, physical, and emotional functioning of affected children and their caregivers. It is a clinical diagnosis based on the Rome IV criteria. Non-pharmacological treatment involves education, demystification, lifestyle advice, and toilet training. Pharmacological treatment consists of disimpaction, maintenance
-
A Retrospective Review of Baclofen Treatment for Children with Rumination Syndrome at a Single Center Pediatric Drugs (IF 3.7) Pub Date : 2023-03-21 Shivani R. Gupta, Peter L. Lu, Karla H. Vaz, Desale Yacob, Jody Wall, Ashley M. Kroon Van Diest, Carlo Di Lorenzo, Neetu Bali
Background Baclofen can decrease rumination frequency in adults with rumination syndrome. Outcomes of baclofen treatment in children with rumination syndrome have not been described. The aim of this study was to examine the safety and efficacy of baclofen in children with rumination syndrome in combination with behavioral therapy at a single center. Methods We performed a retrospective review of children
-
Common Selfcare Indications of Pain Medications in Children Pediatric Drugs (IF 3.7) Pub Date : 2023-03-16 William Zempsky, John Bell, Vanessa Maria Mossali, Preeti Kachroo, Kamran Siddiqui
Pain has a multifaceted impact on individuals worldwide, affecting their physical functioning, emotional well-being, and quality of life. Children (age < 18 years) have a high prevalence of conditions associated with pain, such as toothache, headache, earache, sore throat, and respiratory tract infections, many of which may be accompanied by fever. Globally, the pharmacologic treatment of pain in pediatric
-
Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses Pediatric Drugs (IF 3.7) Pub Date : 2023-02-28 Pierre Desaunay, Léa-Gabrielle Eude, Michel Dreyfus, Cénéric Alexandre, Sophie Fedrizzi, Joachim Alexandre, Faruk Uguz, Fabian Guénolé
-
Antiretroviral Options and Treatment Decisions During Pregnancy Pediatric Drugs (IF 3.7) Pub Date : 2023-02-02 Natalie E. Poliektov, Martina L. Badell
The majority of pediatric human immunodeficiency virus (HIV) infections are the result of vertical transmissions that occur during pregnancy, childbirth, and breastfeeding. The treatment of all pregnant persons living with HIV remains a global health initiative. Early and consistent use of antiretroviral therapy throughout pregnancy and childbirth drastically reduces the risk of perinatal transmission
-
Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives Pediatric Drugs (IF 3.7) Pub Date : 2023-01-27 Jinxia Zhao, Jialu Bian, Yinyu Zhao, Yuanyuan Li, Boyu Liu, Xu Hao, Shiyu He, Lin Huang
As the activity of certain drug metabolizing enzymes or transporter proteins can vary with age, the effect of ontogenetic and genetic variation on the activity of these enzymes is critical for the accurate prediction of treatment outcomes and toxicity in children. This makes pharmacogenetic research in pediatrics particularly important and urgently needed, but also challenging. This review summarizes